Table 10 Associations between GLO1 genotype and breast cancer according to menopausal status and tumor stage
| Â | AA | AE | EE | AE and EE |
|---|---|---|---|---|
Premenopausal | Â | Â | Â | Â |
   Controls, n (%) | 104 (45.2) | 88 (38.3) | 38 (16.5) | 126 (54.8) |
   Cases by stage |  |  |  |  |
Local, n (%) | 26 (23.6) | 50 (45.4) | 34 (31.0) | 84 (76.4) |
OR (95% CI)a | 1.0 | 2.17 (1.16–4.0) | 3.58 (1.82–7.08)b | 2.66 (1.58–4.57) |
Advanced, n (%) | 13 (16.9) | 34 (44.1) | 30 (39.0) | 64 (83.1) |
OR (95% CI)a | 1.0 | 3.05 (1.35–6.65) | 6.29 (2.78–14.34)c | 4.08 (2.02–4.20) |
Postmenopausal | Â | Â | Â | Â |
   Controls, n (%) | 213 (67.8) | 71 (22.6) | 30 (9.6) | 101 (32.2) |
   Cases by stage |  |  |  |  |
Local, n (%) | 55 (24.1) | 98 (43.0) | 75 (32.9) | 173 (75.9) |
OR (95% CI)a | 1.0 | 5.31 (3.39–8.25) | 9.64 (5.59–16.82)d | 6.63 (4.43–9.95) |
Advanced, n (%) | 25 (19.0) | 79 (59.8) | 28 (21.2) | 107 (81.0) |
OR (95% CI)a | 1.0 | 9.44 (5.40–16.55) | 7.99 (3.95–16.30)e | 8.66 (4.89–15.20) |